✦ LIBER ✦

552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

✍ Scribed by C. Delbaldo; J.Y. Pierga; V. Dieras; S. Faivre; M. Bonnay; J.C. Vedovato; M. Mueser; A. Nolting; A. Kovar; E. Raymond

Book ID: 118620725
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 164 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90584-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a phase I trial of the humani

Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Phase I, pharmacokinetic (PK) and biolog

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 145 KB

A phase I dose escalation study of epide

A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors

✍ Karp, D.D; Ferrante, K.J; Tensfeldt, T.G; Thurer, R.L; LoCicero, J; Huberman, M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Cetuximab (C225, Erbitux) in combination

Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 306 KB

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

Phase I dose-finding and pharmacokinetic

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

✍ Noboru Yamamoto; Atsushi Horiike; Yasuhito Fujisaka; Haruyasu Murakami; Tatsu Sh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 367 KB